Ionis Pharmaceuticals annual r&d spending
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ionis Pharmaceuticals R&D Spending Growth & History (IONS)
Ionis Pharmaceuticals's r&d spending was $915.6M for fiscal 2025.
View full Ionis Pharmaceuticals company overviewIonis Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $915.6M | $14.1M | +1.56% |
| 2024 | 2024-12-31 | $901.5M | $1.9M | +0.21% |
| 2023 | 2023-12-31 | $899.6M | $66.5M | +7.98% |
| 2022 | 2022-12-31 | $833.1M | $194.9M | +30.55% |
| 2021 | 2021-12-31 | $638.2M | $107.2M | +20.19% |
| 2020 | 2020-12-31 | $531.0M | $69.5M | +15.06% |
| 2019 | 2019-12-31 | $461.5M | $49.6M | +12.04% |
| 2018 | 2018-12-31 | $411.9M | $39.4M | +10.58% |
| 2017 | 2017-12-31 | $372.5M | $32.1M | +9.43% |
| 2016 | 2016-12-31 | $340.4M | $20.9M | +6.54% |
| 2015 | 2015-12-31 | $319.5M | $80.6M | +33.74% |
| 2014 | 2014-12-31 | $238.9M | $65.2M | +37.54% |
| 2013 | 2013-12-31 | $173.7M | $19.1M | +12.35% |
| 2012 | 2012-12-31 | $154.6M | $1.5M | +0.98% |
| 2011 | 2011-12-31 | $153.1M | $7.9M | +5.47% |
| 2010 | 2010-12-31 | $145.2M | $10.5M | +7.83% |
| 2009 | 2009-12-31 | $134.6M | $28.2M | +26.48% |
| 2008 | 2008-12-31 | $106.4M | — | — |
Ionis Pharmaceuticals quarterly r&d spending
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $217.1M | −$353,000 | −0.16% |
| Q1 2026 | 2026-03-31 | $210.2M | — | — |
| Q4 2025 | 2025-12-31 | $279.6M | — | — |
| Q3 2025 | 2025-09-30 | $217.8M | — | — |
| Q2 2025 | 2025-06-30 | $217.5M | — | — |
| Q4 2013 | 2013-12-31 | $47.8M | $7.9M | +19.84% |
| Q3 2013 | 2013-09-30 | $45.0M | $9.4M | +26.40% |
| Q2 2013 | 2013-06-30 | $42.6M | $2.2M | +5.43% |
| Q1 2013 | 2013-03-31 | $38.3M | −$402,000 | −1.04% |
| Q4 2012 | 2012-12-31 | $39.9M | −$3.1M | −7.15% |
| Q3 2012 | 2012-09-30 | $35.6M | −$4.3M | −10.83% |
| Q2 2012 | 2012-06-30 | $40.4M | $4.4M | +12.29% |
| Q1 2012 | 2012-03-31 | $38.7M | $4.5M | +13.05% |
| Q4 2011 | 2011-12-31 | $42.9M | $3.6M | +9.12% |
| Q3 2011 | 2011-09-30 | $39.9M | $5.2M | +15.00% |
| Q2 2011 | 2011-06-30 | $36.0M | −$3.1M | −7.96% |
| Q1 2011 | 2011-03-31 | $34.2M | $2.3M | +7.06% |
| Q4 2010 | 2010-12-31 | $39.3M | — | — |
| Q3 2010 | 2010-09-30 | $34.7M | $884,000 | +2.61% |
| Q2 2010 | 2010-06-30 | $39.1M | $7.0M | +21.71% |
| Q1 2010 | 2010-03-31 | $32.0M | — | — |
| Q3 2009 | 2009-09-30 | $33.8M | — | — |
| Q2 2009 | 2009-06-30 | $32.1M | — | — |
Ionis Pharmaceuticals r&d spending trends
Over the last five fiscal years, Ionis Pharmaceuticals's r&d spending increased from $531.0M to $915.6M, a change of $384.6M. The latest reported quarter, Q2 2026, shows $217.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ionis Pharmaceuticals source filings ↗